Greenwich LifeSciences Expands FLAMINGO-01 Trial to Up to 200 Sites with City of Hope
Greenwich LifeSciences has activated FLAMINGO-01 Phase III clinical trial sites at four City of Hope locations in Los Angeles, Orange County, Arizona, Atlanta and Illinois, boosting US coverage. With 250 non-HLA-A*02 patients fully enrolled and preliminary data showing a 70–80% recurrence rate reduction, site count may rise to 190–200.
1. Trial Expansion to City of Hope Sites
Greenwich LifeSciences has activated FLAMINGO-01 at four City of Hope network locations in Los Angeles, Orange County, Arizona, Atlanta and Illinois, enhancing geographic reach and access to high-risk early-stage HER2-positive breast cancer patients.
2. Steering Committee Leadership
Hope S. Rugo, M.D., division chief of breast medical oncology at City of Hope and Professor Emeritus at UCSF, has joined the FLAMINGO-01 Steering Committee, bringing decades of expertise in breast cancer clinical trial design and execution.
3. Enrollment and Early Efficacy Data
Over 1,000 patients have been screened with an annual rate of approximately 800; the 250-patient non-HLA-A*02 arm is fully enrolled, and a preliminary analysis shows a 70–80% reduction in recurrence rates following the primary immunization series.
4. Planned Global Site Growth
CEO Snehal Patel noted that with the City of Hope additions, upcoming US Oncology/Sarah Cannon sites and potential UK and Canada centers, FLAMINGO-01’s network could expand from 160 to as many as 190–200 sites worldwide.